Nitzan Rosenfeld

Dxterity Diagnostics, Inc. develops simple and affordable genomic testing solutions for the research, diagnostic, and therapeutic markets. It offers direct to patient platform, digital recruitment, genomic services, and QSR product development. The company was founded by Robert Terbrueggen and Jim Healy in 2006 and is headquartered in Rancho Dominguez, CA.

Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom.

Molten Ventures (Private Equity) (Molten Ventures) is a venture capital firm subsidiary of Molten Ventures Plc founded in 1998 by Simon Christopher Cook and Stuart Malcolm Chapman. The firm is headquartered in London, United Kingdom.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Stanmore Implants Worldwide, Ltd. designs and manufactures bespoke and modular implants for limb sparing and complex joint replacement. It provides massive endoprothesis tumour systems for orthopedic skeletal locations including the femur, tibia, knee, pelvis and humerus. The firm also offers computer assisted orthopedic surgeries. The company was founded on February 19, 1996 and is headquartered in Elstree, the United Kingdom.

The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40.

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

The Personalized Medicine Coalition promotes the understanding and adoption of personalized medicine concepts, services, and products. The private company is based in Washington and was founded by Patrick F. Terry.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

The British Association for Cancer Research (BACR) is a professional membership association for all those working and studying in cancer research within and beyond the UK. The BACR is based in Sutton, UK. The BACR aims to promote the advance of research in relation to all aspects of cancer and encourage the exchange of information. The British company provides educational and training opportunities for all those involved in the cancer field, particularly the next generation of cancer research professionals. The private company also organizes scientific conferences and workshops, and offer meeting bursaries and fellowships, to enable their membership to attend cancer-focused events around the world.

Pictor Ltd. operates as a biotechnology company. It develops technology for multiplexed testing for blood and biological fluids. The firm?s products include PictArrayTM ToRCH ELISA, ENA ELISA, and HAE ELISA Kit. The company was founded by Krishnanand Kumble and Sarita Kumble in 2005 and is headquartered in Auckland, New Zealand.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Ieso Digital Health Ltd. provides Internet enabled mental health services to health providers, private individuals and businesses. The firm engages in delivering cognitive behavioral therapy. It offers anxiety, bereavement, child and family, depression, drug and alcohol misuse, eating disorder, managing anger, managing pain, obsessive compulsive disorder, panic, phobia, post traumatic stress, relationship, sexual difficulty, sports psychology, stress management, and terminal illness therapy services. The company was founded by Barnaby Perks, Sue Wright and Nadine Field in 2000 and is headquartered in Cambridge, the United Kingdom.

Nascient Ltd. develops a novel antibody treatment for rheumatoid arthritis. The company was founded by Phil Bland-Ward, Kim Midwood and Nigel Robert Burns in 2012 and is headquartered in London, the United Kingdom.

Puridify Ltd. develops bioprocessing technologies. It develops a platform purification technology that will improve processing opportunities and reduce costs. The company was founded by Oliver Hardick, Iwan Thomas Roberts and Thomas Edward Haywood in 2013 and is headquartered in Stevenage, the United Kingdom.

Memed Diagnostics Ltd. engages in the development and commercialization of diagnostic solutions for inflammatory and infectious diseases. Its products include MeMed BV and MeMed Key, devices for blood test and quantitative diagnostic immunoassays. The company was founded by Eran Eden and Kfir Oved in 2009 and is headquartered in Tirat Carmel, Israel.

Bantam Pharmaceutical LLC is a privately funded biopharmaceutical company that specializes in the discovery and development of novel therapeutics for difficult-to-treat hematological and solid tumors. The company is based in New York, NY. The company is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies. Bantam's clinical development strategy is focused on areas of unmet clinical need, with initial phase I/II clinical trials planned in relapsed/refractory B-cell hematological malignancies, including diffuse large B-cell lymphoma. The company was founded by Victor F. Keen, and Michael T. Stocum has been the CEO of the company since 2019.

Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom.

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom.

BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel.

Tailor Bio Ltd. provides research and experimental development on biotechnology. The company was founded on September 26, 2019 and is headquartered in London, the United Kingdom.

Veryan Medical Ltd. develops and commercializes novel vascular stent technology. The firm's products are designed to clinical performance and bio-mechanical performance of stented vessels. The company was founded by Colin G. Caro, Charles Richard Taylor and Paul Burke Gilson in 2003 and is headquartered in Oxford, the United Kingdom.